EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has initiated a public offering of $100 million in common stock to support its clinical development and pipeline initiatives [1][3]. Group 1: Offering Details - The public offering consists of $100 million in shares, with an option for underwriters to purchase an additional $15 million within 30 days [1][2]. - J.P. Morgan, Citigroup, and Guggenheim Securities are the joint book running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support earlier stage pipeline initiatives and general corporate purposes [3]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, leveraging its proprietary Durasert E™ technology for sustained intraocular drug delivery [7][8]. - The lead product candidate, DURAVYU™, is currently in Phase 3 clinical trials for wet AMD and Phase 2 trials for DME, with topline data expected in Q1 2025 and 2026 respectively [7][8].